PTC Inc. (NASDAQ:PTC) Q1 2026 Earnings Call Transcript February 4, 2026 PTC Inc. beats earnings expectations. Reported EPS is $119797.12, expectations were $1.59. Operator: Good evening, ladies and ...

DENVER (KDVR) — The Colorado Department of Revenue revealed on Wednesday how much eligible Coloradans can receive through its PTC Rebate Program and unveiled a new tax credit for Coloradans with ...

Morphy Richards OFR Room Heater, 09 Fin 2000 Watts Oil Filled Room Heater , ISI Approved (OFR 9 Grey)View Details Every product we recommend is chosen through a combination of Primary Research and ...

It has been about a month since the last earnings report for PTC Inc. (PTC). Shares have added about 2.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...

Revenue also exceeded forecasts, reaching $894 million compared to the anticipated $750.87 million, marking a 19.06% surprise. Despite these strong earnings, Mizuho has lowered its price target for ...

PTC isn't receiving much help from macroeconomic conditions, but its key metric is still growing strongly as it adds tangible value. Infusing AI into its software will enhance the efficacy of the ...

PTC Inc (NASDAQ:PTC) delivered a strong performance in its fourth-quarter earnings for fiscal year 2025, significantly exceeding analysts’ expectations. The company reported earnings per share (EPS) ...

PTC (PTC) shares have been fairly stable recently, with a slight uptick at the close. Despite some mild fluctuations in the past month, investors are watching for signals that could shape the stock’s ...

Seth MacFarlane once famously called the PTC "like getting hate mail from Hitler." Now they've filed for Chapter 11. By James Hibberd Writer-at-Large The organization’s tagline was “Because Our ...

Management believes that the commercial opportunity, combined with its cash reserves, will enable its cash flow to reach breakeven. The drug has been approved in the U.S. and Europe, and PTC ...

The U.S. Food and Drug Administration has turned away PTC Therapeutics' proposed vatiquinone treatment for the rare, inherited neurodegenerative disorder Friedreich's ataxia over concerns about the ...